HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Interferon Alfa-2a (Interferon Alfa 2a)

Subscribe to New Research on Interferon Alfa-2a

A recombinant alfa interferon consisting of 165 amino acids with lysine at position 23 and histidine at position 34. It is used extensively as an antiviral and antineoplastic agent.

Also Known As:

Interferon Alfa 2a; Roferon-A; Recombinant Interferon alpha-2a; Ro 22-8181; Interferon Alfa-2a, Recombinant; Interferon alpha-2a, Recombinant; Recombinant Interferon Alfa 2a; Recombinant Interferon alpha 2a; Ro 22 8181; Ro 228181; Roferon A; RoferonA; Recombinant Interferon Alfa-2a

Networked: 457 relevant articles (57 outcomes, 127 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Xie, Yao: 6 articles (07/2007 - 02/2004)
2.	Escudier, Bernard: 4 articles (05/2010 - 12/2007)
3.	Zeuzem, Stefan: 4 articles (01/2009 - 12/2002)
4.	Xu, Dao-zhen: 4 articles (07/2007 - 02/2004)
5.	Chung, Raymond T: 3 articles (12/2010 - 07/2004)
6.	Ravaud, Alain: 3 articles (05/2010 - 12/2007)
7.	Lu, Zhi-meng: 3 articles (07/2007 - 02/2004)
8.	Li, Ming-hui: 3 articles (07/2007 - 08/2006)
9.	Wang, Yu-ming: 3 articles (07/2007 - 02/2004)
10.	Zhang, Shu-lin: 3 articles (07/2007 - 02/2004)

Related Diseases

1.	Chronic Hepatitis C 01/01/1997 - "[The therapeutic efficacy of interferon-alfa-2a (Roferon-A) in chronic hepatitis C]." 03/01/1999 - "Long-term efficacy of recombinant interferon alpha 2a in the treatment of chronic hepatitis C: a randomized prospective study comparing two dose schedules in Chinese patients." 12/01/1996 - "A prospective, randomized trial comparing lymphoblastoid to recombinant interferon alfa 2a as therapy for chronic hepatitis C." 06/01/1996 - "Randomized trial comparing three different regimens of interferon alfa 2a in chronic hepatitis C." 08/01/2006 - "The patients with chronic hepatitis C were treated with PEG-IFN alpha -2a and Roferon-A for 24 weeks. "
2.	Renal Cell Carcinoma (Grawitz Tumor) 07/01/1993 - "Three trials were conducted to define the efficacy and toxicity of interferon alfa-2a in the treatment of metastatic renal cell cancer. " 07/01/1993 - "Interferon alfa-2a had minimal antitumor activity in patients with advanced renal cell carcinoma and long-term survival was achieved in a small proportion of patients. " 07/01/1993 - "Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up." 12/01/1988 - "Eighteen patients with advanced renal cell carcinoma were treated with recombinant interferon alpha-2a (18 million IU s.c. " 01/01/1987 - "This methodology was evaluated during a clinical trial of recombinant interferon alfa-2a (rIFN alfa-2a) for the treatment of 10 metastatic renal cell carcinoma patients. "
3.	Infection 06/01/2004 - "Because of lack of in vivo antiviral activity against BVDV, recombinant human interferon alfa-2a has little promise as a therapeutic agent for the treatment of BVDV infection, at least in persistently infected cattle. " 11/15/2001 - "Early use of interferon alfa-2a can stop HCV infection." 01/01/1995 - "The other 30 patients with recurrent or multiorgan infections received 3 courses with 12 x 10(6) IU interferon alfa-2a subcutaneously. " 10/01/1993 - "Treatment of respiratory syncytial virus infection with recombinant interferon alfa-2a." 02/01/1987 - "Changes of hepatitis B virus (HBV) markers during prolonged recombinant interferon alpha-2A treatment of chronic HBV infection."
4.	Neoplasms (Cancer) 04/15/1986 - "A Phase II study was then conducted in 641 patients to evaluate the efficacy of interferon alfa-2a in a number of disseminated malignant neoplasms. " 07/01/1997 - "Moreover, this interaction appeared to be closely associated with a soluble factor produced by the tumor T-cell infiltrate and was at least partially blocked by interferon alfa-2a." 11/01/1996 - "The use of interferon alfa-2a for 9 months stopped progression of the tumor." 01/01/1995 - "Patients with bidimensionally measurable disease were treated with Roferon-A 1 million units subcutaneously daily and tumor assessments were conducted on a monthly basis. " 08/01/1993 - "Intralesional interferon alfa-2a (IFN alfa-2a) has been shown to have activity against different epithelial tumors and to have an antiviral effect. "
5.	Mycosis Fungoides 10/01/1991 - "This study was designed to evaluate the therapeutic efficacy and toxicity of recombinant interferon alpha-2a (rIFN alfa-2a) given as initial systemic therapy in untreated mycosis fungoides and/or Sezary's syndrome patients, at a slowly escalating schedule up to the maximal tolerated dose. " 01/01/1995 - "To investigate the efficacy of combined topical therapy and systemic interferon alfa-2a in patients with mycosis fungoides (MF) and the Sézary syndrome (SS). " 01/01/1990 - "We previously demonstrated that recombinant interferon alfa-2a (IFN-alfa) in a dose of 50 X 10(6) U million units (MU)/m2 intramuscularly (IM) three times per week has efficacy against mycosis fungoides (MF) and the Sézary syndrome (SS). " 01/01/1990 - "Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the Sézary syndrome." 06/24/1989 - "Autoimmune haemolytic anaemia associated with interferon alfa-2a in a patient with mycosis fungoides."

Related Drugs and Biologics

1.	Interferons
2.	Interferon Alfa-2a (Interferon Alfa 2a)
3.	Ribavirin (Virazole)
4.	Fluorouracil (Carac)
5.	Leucovorin (Folinic Acid)
6.	Interferon-alpha (Interferon Alfa)
7.	peginterferon alfa-2a (Pegasys)
8.	Isotretinoin (Accutane)
9.	Interferon Alfa-2b (Interferon Alfa 2b)
10.	Interleukin-2 (IL2)

Related Therapies and Procedures

1.	Intralesional Injections
2.	Drug Therapy (Chemotherapy)
3.	Immunotherapy
4.	Bone Marrow Transplantation (Transplantation, Bone Marrow)
5.	Photopheresis